Coherus BioSciences (NASDAQ:CHRS) Stock, Quote.Headers.trade-ideas

Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACRS

AFRM

AGFY

BFRG

CHPT

CHRS

CISS

CLDI

COMM

CXAI

DWAC

FRES

FSLY

FTEL

GILD

Intelligent Bio Solutions Inc. - Common Stock

INBS

Airspan Networks Holdings Inc. Common Stock

MIMO

NEXI

NVVE

OCTO

PCSA

RILY

RVSN

SAVE

SGMT

STNE

TAOP

TNYA

UPST

VIRI

WISA

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session.

B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2.

CommScope shares dipped 6.9% to $2.2150 on Monday.

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

cancer

Biotech

Equities

Health Care

Asset Sales

General

SDZNY

SDZXF

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS&#39; focus on oncology and will help reduce debt and overhead costs.

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?

Pre-Market Outlook

ASTL

CELU

GBNH

HNRA

HUBC

MARK

Nuveen Insured California Premium Fund Ii

PRCH

TCBP

UNCY

Shares of  Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Coherus BioSciences Inc

WIIM

Coherus Biosciences shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $4 to $1.5.

UBS analyst Ashwani Verma downgrades Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) from Buy to Neutral and lowers the price target from $4 to $1.5.

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Coherus BioSciences to Neutral, Lowers Price Target to $1.5

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q2 financial results.

Guidance

Coherus BioSciences Sees FY24 R&D And SG&A Expenses $250M-$265M

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.29) by 51.72 percent. The company reported quarterly sales of $65.000 million which beat the analyst consensus estimate of $61.366 million by 5.92 percent. This is a 10.70 percent increase over sales of $58.716 million the same period last year.

Earnings

Earnings Beats

Coherus BioSciences Q2 2024 Adj. EPS $(0.14) Beats $(0.29) Estimate, Sales $65.000M Beat $61.366M Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $12 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and lowers the price target from $9 to $8.

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $8

Coherus BioSciences To Divest YUSIMRY In $40M Upfront All Cash Transaction

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and lowers the price target from $8 to $7.

Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and raises the price target from $11 to $12.

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12

Coherus BioSciences shares are trading lower after the company reported better-than-expected Q1 financial results.

Earnings Misses

Coherus BioSciences Q1 2024 Adj EPS $(0.32) Misses $(0.24) Estimate, Sales $77.063M Miss $80.248M Estimate

<ul>
<li>New $38.7 million term loan with a May 2029 maturity</li>
<li>$37.5 million royalty monetization financing based on future sales of LOQTORZI&nbsp;and UDENYCA</li>
</ul>

Coherus Announces Full Repayment of Pharmakon Advisors $75M Term Loan

Contracts

Coherus To Collaborate With Cancer Research Institute On Novel Combination Evaluating LOQTORZI With ENB Therapeutics' ENB-003 For Treatment Of Ovarian Cancer

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion – – Mechanism may enhance antitumor responses with immunotherapy – – First novel immuno-oncology product candidate discovered and developed by Coherus – – The CHS-1000 IND submission is planned for Q2 2024 –
REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 (also known as LILRB2) with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype.
"Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance. The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response. Reprogramming myeloid cells in the tumor microenvironment holds promise as a new immuno-therapy approach with the aim to overcome resistance to I-O therapy and potentially provide benefit to more cancer patients," said Theresa LaVallee, Ph.D., Chief Development Officer at Coherus. "CHS-1000 is our first internally discovered development candidate, and we are excited to be filing the IND this quarter. We plan to advance CHS-1000 into the clinic both as a single agent and in combination with LOQTORZI&#xAE;."
These data will be presented today in a poster session, and the poster will be available for download at the time of the presentation:
Abstract: 1364/15 Title: <a href="https://www.globenewswire.com/Tracker?data=b-uQ9Bkof9Sji0aB982AtyOYvcv5Xl-9Bg9u2FJd0Z1liW4GB5t0Qgq2Ep1KWsfekasaWY-N33KqwYrlBZtQxusWWKPTiS-GA0mwE7o2RvwYkQg0uXBMa9gl8RdlqFqrV0THxMh1zr2rspAeYvllpvOG6lwLFIVSKQqQWd4DGjecPUH8-DUNb2WvexstyaFmngapN03lg6fyasDGuts65XpKVosuEY8LcQlbErxzHf8tVk_AeFQzQy_1mf9ijcO8Rf11betnAxEADYdPYqkyl5D_0CrjbVV2XycAXZ-ifLk=">Characterization of CHS-1000, an Fc-modified anti-ILT4 monoclonal antibody for reprogramming suppressive myeloid cells in solid tumors</a> Presenting author: Narendiran Rajasekaran, Ph.D. Session PO.IM01.02 – Immune Checkpoints and Inhibitory Molecules 1 Date and Time: Monday, April 8, 2024, 9:00 a.m. – 12:30 p.m. Pacific Daylight Time
Poster data are summarized as follows:
<ul>
<li>CHS-1000 binds specifically and selectively to human ILT4 (LILRB2) with high affinity and showed no cross-reactivity to other LILRB family members.</li>
<li>CHS-1000 efficiently blocks the interaction of ILT4 with its ligands, HLA-A and HLA-G, and reverses ILT4-mediated immunosuppressive functions, leading to activation of M1 macrophages, dendritic cells, and T cells and increases in pro-inflammatory cytokine secretion in in vitro assays.</li>
<li>CHS-1000 is Fc silent and lacks effector function activity in in vitro assays consistent with the engineered modification of the Fc region of the antibody. It also has IgG1‑like PK parameters in human FcRn transgenic mice.
<ul>
<li>ILT4 and CD163, a marker of suppressive (M2) macrophages, are highly expressed in a broad range of solid tumors.</li>
</ul>
</li>
</ul>

Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and lowers the price target from $13 to $11.

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $13 price target.

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target

Coherus BioSciences shares are trading lower after the company reported worse-than-expected Q4 financial results.

Coherus BioSciences GAAP EPS of -$0.11 beats by $0.09, revenue of $65M beats by $8.58M

Coherus Biosciences (CHRS) has shared an announcement. Bryan McMichael, previously serving in key financial roles within the company since March 20...

Coherus Biosciences Appoints Bryan McMichael as CFO

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Coherus BioSciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/chrs-stock-quote/">CHRS</a>) just reported results for the second quarter of 2024.<ul><li>Coherus BioSciences reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -16 cents.</li><li>The company reported revenue of $64.98 million.</li><li>This was 1.28% better than the analyst estimate for revenue of $64.16 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/chrs-stock-earnings-coherus-biosciences-for-q2-of-2024/">CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024

Coherus Biosciences (CHRS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao fro...

Buy Rating Justified by Coherus Biosciences' Strong Udenyca Sales and Promising Pipeline

TD Cowen analyst Michael Nedelcovych has reiterated their bullish stance on CHRS stock, giving a Buy rating today. Michael Nedelcovych has given hi...

Strong Financial Performance and Market Share Growth Underpin Buy Rating for Coherus Biosciences

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

In a report released on August 9, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), wit...

Strong Performance and Promising Outlook Justify Outperform Rating for Coherus Biosciences

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Coherus Biosciences (CHRS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ashwani Verm...

Coherus Biosciences: Hold Rating with Downward Revenue Projections and Price Target Revision

UBS cuts Coherus to neutral, cites limited growth opportunities

AMGN

SHJBF

Press Releases

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

Financing

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Management

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Comments

Coherus BioSciences

Coherus BioSciences (CHRS) Forecast

Coherus BioSciences (NASDAQ:CHRS) Stock, Quote.Headers.trade-ideas